Prostate Cancer: From Pathology to Novel Therapeutic Approaches

Dear Colleagues,

Prostate cancer remains the second most common cancer in men, with a diverse course from indolent cases to lethal disease. Understanding of prostate cancer biology, genetics, and molecular pathology has emerged, and several new drugs have improved outcomes of metastatic castrate-resistant prostate cancer. However, several tasks remain to be completed, for example, novel screening biomarkers to complement PSA or credential differentiation of indolent disease from aggressive course, molecular stratification of PCa using advanced approaches, novel treatment strategies for better outcomes in high-risk locally advanced cancer or metastatic disease, and the discovery of surrogate biomarkers for durable overall survival benefit. This Special Issue on “Prostate Cancer: From Pathology to Novel Therapeutic Approaches” aims to publish cutting-edge research on both preclinical and clinical studies on prostate cancer, including a comprehensive overview of tumor progression in association with the tumor microenvironment, metabolism, metastatic process, cancer treatment, immune response, or drug resistance. Review articles as well as original studies will be considered for publication. We hope that both academy and clinics working on prostate cancer will find this platform useful. We look forward to receiving exceptional submissions.

Dr. Gvantsa Kharaishvili
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.